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ABSTRACT 
Chronically haemodialysed end-stage renal disease patients are at high risk of 
morbidity arising from complications of dialysis, the underlying pathology that has led 
to renal disease and the complex pathology of chronic kidney disease. Anaemia is 
commonplace and its origins are multifactorial, involving reduced renal erythropoietin 
production, accumulation of uremic toxins and an increase in erythrocyte fragility. 
Oxidative damage is a common risk factor in renal disease and its co-morbidities, 
and is known to cause erythrocyte fragility. Therefore we have investigated the 
hypothesis that specific erythrocyte membrane proteins are more oxidised in end-
stage renal disease patients and that vitamin C supplementation can ameliorate 
membrane protein oxidation. 
Eleven patients and fifteen control subjects were recruited to the study. Patients were 
supplemented with 2 x 500mg vitamin C per day for four weeks. Erythrocyte 
membrane proteins were prepared pre- and post-vitamin C supplementation for 
determination of protein oxidation. Total protein carbonyls were reduced by vitamin C 
supplementation but not by dialysis when investigated by enzyme linked 
immunosorbent assay. Using a western blot to detect oxidised proteins, one protein 
band, later identified as containing ankyrin, was found to be oxidised in patients but 
not controls and was reduced significantly by 60% in all patients after dialysis and by 
20% after vitamin C treatment pre-dialysis. Ankyrin oxidation analysis may be useful 
in a stratified medicines approach as a possible marker to identify requirements for 
intervention in dialysis patients. 
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INTRODUCTION 
In the absence of kidney transplantation, chronic haemodialysis is a life-saving 
treatment for patients with end-stage renal disease (ESRD) irrespective of its 
aetiology. However, there are many complications in chronically haemodialysed 
patients. These can be classified into two general categories: a) specific 
complications which are a result from the haemodialysis treatment itself, and b) 
complications of the primary disease which ultimately led to its ESRD [1]. The most 
common complications are the following: anaemia, congestive heart failure, vascular 
and cardiac calcifications, hypertension, dyslipidaemia, accelerated atherosclerosis, 
immune deficiency, inflammation, nausea and anorexia, malnutrition, gastrointestinal 
bleeding, hyperparathyroidism and bone disorders, dementia and infection with 
blood-borne viruses - mainly hepatitis B and C. These complications, together with 
additional co-morbidities and the complex pathology contribute to very high morbidity 
and mortality among chronically haemodialysed patients [2]. 
Many clinical chemistry biomarkers have been tested for their power to predict 
morbidity and mortality in chronically haemodialysed patients; serum albumin [3] and 
high sensitivity C-reactive protein have been recognised as the most appropriate 
biomarkers for predicting all-cause mortality [4,5], mainly because of their high 
reliability, stability and relative ease of analysis. There is emerging evidence that 
biomarkers of plasma (anti)oxidant status could also predict the all-cause mortality in 
chronically haemodialysed patients [6]. 
Oxidative damage is a common underlying feature of chronic haemodialysis [7-9] and 
may contribute to anaemia [10-13] through increasing the extent and nature of 
oxidation and fragility of erythrocyte membranes. Oxidative damage has been 
attributed to: a) the uremic syndrome itself [14,15], and b) the bio-incompatibility of 
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the haemodialysis membrane [16]. To address this, vitamin E is used for both coating 
of the haemodialysis membrane [17,18], and as an oral supplementation [19] and 
has been proven to reduce the recombinant human erythropoietin (rHuEPO) 
requirement in patients to mitigate anaemia. Besides erythropoietin deficiency, and 
even in the presence of erythropoiesis stimulating agents, the reduced erythrocyte 
survival time is another important cause for anaemia in chronically haemodialysed 
patients. It is generally accepted that the toxic uremic environment accounts for the 
decreased erythrocyte life-span and this is not explained by mechanical damage 
from the dialysis membrane [20]. 
Previous studies have shown a high prevalence of ascorbic acid deficiency in 
chronically haemodialysed patients which is accompanied by increased levels of 
oxidative stress biomarkers, thus suggesting that ascorbate supplementation may be 
of value [21]. Therefore, vitamin C as an oral [22] or intravenous [23] supplement is 
very often used as an antioxidant treatment in chronically haemodialysed patients, 
alone or in combination with vitamin E [24]. There is also evidence that vitamin C is 
effective in increasing the haemoglobin concentrations in patients who are hypo-
responsive on treatment with erythropoietin, and/or decreasing of the rHuEPO 
requirements [25,26]. However, there may be adverse effects of vitamin C 
supplementation, a) especially in relation to the hyperoxalemia [27], and b) its 
paradoxical pro-oxidant effect in the presence of iron [28]. 
In summary, the molecular mechanisms involved in the development of anaemia in 
ESRD patients who are on chronic haemodialysis are not completely clear. Knowing 
that the erythrocyte membrane plays a key role in its mechanical properties and 
survival, a recent study investigated the erythrocyte membrane proteome in a) non-
dialysed chronic kidney disease patients, b) erythropoietin/haemodialysis-treated 
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chronic kidney disease patients, and c) healthy individuals. Differentially expressed 
erythrocyte membrane proteins were observed between the groups of subjects under 
study, which could be potentially relevant for understanding of anaemia in uremic 
syndrome and chronic haemodialysis [29]. 
Based on the close interconnection between oxidative stress, anaemia and 
decreased rHuEPO responsiveness in chronically haemodialysed patients, we 
hypothesise that specific erythrocyte membrane protein oxidation contributes to the 
pathogenesis of anaemia in these patients. Thus, the aim of our study is to determine 
the total erythrocyte membrane protein carbonyls, to identify specific erythrocyte 
membrane proteins which are more oxidised in chronically haemodialysed patients, 
and to understand the effects of short-term oral vitamin C supplementation and 
dialysis on oxidative damage. 
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PATIENTS AND METHODS 
 
PATIENTS 
All 26 patients attending the two morning shifts of the Department of Haemodialysis 
at the Clinical Hospital in Stip, Republic of Macedonia, receiving chronic 
haemodialysis treatment were considered for enrolment in the study. An initial 
questionnaire revealed that 13 of the 26 patients were taking intravenous vitamin C 
supplementation of 500mg after each haemodialysis session, and one was taking 
1000mg of vitamin C per day as an oral supplementation so these patients were 
excluded from the study. In addition, one of the patients was on haemodialysis 
treatment for less than 1 year, and was also excluded. The remaining 11 patients 
were consented and enrolled in the study. None of them reported use of any 
antioxidants and supplements. 
Blood for analysis was taken immediately before the start of the haemodialysis 
session, after an overnight fast, in a blood collection tube containing heparin as an 
anticoagulant. Before haemodialysis, blood was also taken in an additional EDTA 
blood collection tube. This sample was used for analysis of the full blood count (FBC) 
on a 3-part differential automatic haematology analyser (Cobas Micros, Roche). The 
FBC analysis was run in the Laboratory for Biochemistry at the Clinical Hospital in 
Stip within few hours after the sampling. In addition, blood was taken again in a 
heparin containing blood collection tube, immediately after the haemodialysis 
session. 
Blood samples from heparin containing collection tubes were processed immediately 
after the sampling. After the plasma and buffy coat removal, erythrocytes were 
washed 3 times with 4mL of physiological saline, each time discarding the small 
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quantity of the erythrocytes and remaining leucocytes from the top layer. Washed 
erythrocytes from the bottom of the tube were carefully aspirated, transferred in 
another tube, lysed with 2mL of cold water, and immediately frozen at -80°C. 
Starting the next day after the initial sampling, an oral vitamin C supplementation 
(Pliva, Zagreb, Croatia) was provided to the patients enrolled in the study, in a dose 
of 2 x 500mg per day, for a period of four weeks. All of the patients enrolled in the 
study had taken the vitamin C supplementation regularly as assessed by pill return 
and interview, except of one of them who occasionally missed some of the doses. 
None of the patients reported any adverse effects. In addition, none of them 
experienced any acute inflammatory or infectious disease. During the 4 weeks study 
period all parameters of the haemodialysis treatment were kept constant for each 
patient. 
After four weeks, the sampling was repeated before the haemodialysis session only, 
and the same protocol for preparation of the samples was followed. On the day of the 
sampling the patients did not take their dose of the vitamin C. A schematic 
representation of the study design is given in Figure 1. 
A group of 15 healthy volunteers, non-smokers, with normal FBC and without any 
acute or chronic disease, taking no medications nor any vitamins or supplements, 
were included in the study as controls. Fasting blood samples (after an overnight 
fast) were taken for analysis. 
All patients and control subjects gave informed written consent for participation in the 
study. This study was performed in accordance to the ethical principles for medical 
research involving human subjects (Declaration of Helsinki, 2008). The study was 
approved by the Institutional Review Board of the Clinical Hospital in Stip, and 
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conducted under ethical guidance of Dr. Slave Dimitrov, as stated in document 
No.1/12 from 28.05.2012, Clinical Hospital in Stip, Republic of Macedonia. 
Erythrocyte lysates were transported under dry ice to Aston University in 
Birmingham, United Kingdom, and were kept at -80°C. All analyses were performed 
within 9 months of the blood withdrawal. 
 
METHODS 
 
PREPARATION OF ERYTHROCYTE MEMBRANES 
The erythrocyte membranes were prepared in accordance to the previously 
published protocols [30-32], slightly modified. Namely, 1mL of the lysed erythrocytes, 
well mixed, was centrifuged for 15 minutes at 16,600g at 4ºC and the supernatant 
discarded. Erythrocyte membranes were then mixed thoroughly using a pipette and 
resuspended in a high-salt buffer (1mL; 2.9g NaCl in 100mL lysis buffer. Lysis buffer: 
5mM Na2HPO4, 1mM Na2EDTA, 1mM phenylmethanesulfonyl fluoride, pH 8.0). 
Following vortex, erythrocyte membranes were centrifuged for 15 minutes at 16,600g 
at 4ºC and supernatant discarded. Erythrocyte membranes were then mixed 
thoroughly using a pipette and resuspended in 1mL lysis buffer. Following vortex, 
erythrocyte membranes were centrifuged for 15 minutes at 16,600g at 4ºC and 
supernatant discarded. To remove any particulate matter, the erythrocyte 
membranes were mixed well and resuspended in 1mL lysis buffer. Following vortex, 
erythrocyte membranes were centrifuged at 200g for 30 seconds. Supernatant was 
removed, further centrifuged for 15 minutes at 16,600g at 4ºC and subsequent 
supernatant discarded. Erythrocyte membranes were then mixed thoroughly using a 
pipette and resuspended in 1mL lysis buffer. Following vortex, erythrocyte 
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membranes were centrifuged for 15 minutes at 16,600g at 4ºC and supernatant 
discarded. The washing steps were repeated until supernatant was completely clear 
and a pale yellow pellet visible. Erythrocyte membrane pellets were resuspended 
with 1% triton X-100 in lysis buffer (100µL), mixed well by vortex and stored at -80ºC. 
Protein concentration was determined using the bicinchoninic acid (BCA) assay. 
 
MEASUREMENT OF TOTAL PROTEIN CARBONYLS IN ERYTHROCYTE 
MEMBRANES 
Reduced and oxidised bovine serum albumin (BSA) was prepared for carbonyl 
standards and the enzyme linked immunosorbent assay (ELISA) was performed as 
described by Carty et al. (2000) [33]. 
 
SDS-PAGE ELECTROPHORESIS 
Erythrocyte membrane preparations were mixed in a 1:1 ratio with Laemmli buffer 
(2X, Sigma, UK), boiled for 5 minutes at 95°C and separated by reducing SDS-PAGE 
using 10% polyacrylamide gels. Each gel included lanes for protein markers (Bio-Rad 
Precision Plus Protein Standard Kaleidoscope, 10 - 250kDa), an oxidised BSA 
sample (positive control), and erythrocyte membrane preparations. Electrophoresis 
was undertaken using a Mini-PROTEAN® Tetra Cell (Bio-Rad) and a constant 
voltage (115V) was applied to each gel for 1 hour 45 minutes or until the gel front had 
migrated fully. Gels were electrophoresed in parallel. One gel was stained with 
Flamingo fluorescent stain (Bio-Rad) according to the manufacturer’s protocol, while 
the other one was used for western blot analysis. The stained gels were scanned on 
a Pharos FX Plus Molecular Imager (Bio-Rad). 
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WESTERN BLOT ANALYSIS 
Erythrocyte membrane proteins were transferred to Hybond-P® PVDF membranes 
(GE Healthcare, Amersham, UK). 
Briefly, for analysis of protein carbonyls the PVDF membranes were washed six 
times for 5 minutes in 0.05% Tween 20, in Tris buffered saline (TBS) [34]. The 
proteins were derivatised using 1mM dinitrophenylhydrazine (DNPH) in 2M 
hydrochloric acid for one hour. Membranes were washed six times for 5 minutes in 
0.05% Tween 20, in TBS and blocked overnight at room temperature with 0.1% 
Tween 20 and 3% BSA in TBS. Membranes were further washed six times for 5 
minutes in 0.05% Tween 20, in TBS and incubated for two hours with monoclonal 
mouse anti-DNP (Sigma, UK) antibody diluted at 1:1000 with 0.2% BSA in TBS. 
Membranes were washed a further six times for 5 minutes with the same washing 
buffer and then incubated for one and a half hour with peroxidase conjugated rat anti-
mouse IgE antibody (AbD Serotec) diluted at 1:10000 with 0.2% BSA in TBS. 
Subsequently, membranes were washed five times for 5 minutes with 0.05% Tween 
20, in TBS and once with TBS only. Oxidised erythrocyte membrane proteins were 
visualised using ECL+ chemiluminescence (GE Healthcare, Amersham, UK), and 
protein bands scanned using a molecular imager GS-800 Calibrated Densitometer 
(Bio-Rad). 
For anti-ankyrin western blot, membranes were washed six times for 5 minutes in 
0.05% Tween 20 in TBS and incubated for two hours with rabbit anti-human ankyrin 
antibody (Abcam, UK; raised against C-terminal residues1862-1874 of human 
erythroid ankyrin) diluted at 1:1000 with 0.2% BSA in TBS. Membranes were washed 
a further six times for 5 minutes with the same washing buffer and then incubated for 
one and a half hour with peroxidase conjugated mouse anti-rabbit IgG antibody 
Page 12 of 39 
 
(Sigma) diluted at 1:10000 with 0.2% BSA in TBS. Subsequently, membranes were 
washed and visualised for ankyrin as above. 
 
LC-MS/MS 
Flamingo fluorescence-stained bands were excised, divided into ~2mm3 cubes and 
destained with acetonitrile followed by 100mM ammonium bicarbonate. This cycle 
was repeated until gel pieces were destained. Gel pieces were dried (vacuum 
centrifugation; 5 min) and rehydrated in 10mM Dithiothreitol and 100mM ammonium 
bicarbonate and reduced at 60°C for 15 min. The liquid was removed and replaced 
with 50mM iodoacetamide and 100mM ammonium bicarbonate. Gel pieces were 
incubated at room temperature in the dark for 45 min and then washed with 100mM 
ammonium bicarbonate. After drying the gel (vacuum centrifugation; 5 min) 0.3µg 
trypsin gold (Promega, WI, USA) was added and shaken at room temperature for 30 
min, before dilution with 100mM ammonium bicarbonate. Hydrolysis was allowed to 
occur overnight (~16 h) at 37°C. Peptides were extracted with the initial solution of 
2% acetonitrile and 0.1% formic acid in water was added and shaken for 30 minutes. 
Supernatant was removed to a clean plate. A second peptide extraction was 
performed using 40% acetonitrile and 0.1% formic acid in water, shaken for 30 
minutes at room temperature. The supernatant was removed, pooled with the 
previous extracted peptides and dried in an evaporator. The samples were re-
suspended in 0.1% formic acid/water. 
UltiMate® 3000 HPLC series (Dionex, Sunnyvale, CA USA) was used for peptide 
concentration and separation. Samples were separated in Nano Series™ Standard 
Columns 75 µm i.d. x 15 cm, packed with C18 PepMap100, 3 µm, 100Å (Dionex, 
Sunnyvale, CA USA). The gradient used was from 3.2% to 44% solvent B (0.1% 
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formic acid in acetonitrile) for 30 min. Peptides were eluted directly (~ 350 nL min-1) 
via a Triversa Nanomate nanospray source (Advion Biosciences, NY) into a LTQ 
Orbitrap Velos ETD mass spectrometer (ThermoFisher Scientific, Germany). The 
data-dependent scanning acquisition was controlled by Xcalibur 2.1 software. The 
mass spectrometer alternated between a full FT-MS scan (m/z 380 – 1600) and 
subsequent collision-induced dissociation MS/MS scans of the 7 most abundant ions. 
Survey scans were acquired in the Orbitrap with a resolution of 60 000 at m/z 400 
and automatic gain control 1x106. Precursor ions were isolated and subjected to CID 
in the linear ion trap with automatic gain control 1x105. Collision activation for the 
experiment was performed in the linear trap using helium gas at normalised collision 
energy to precursor m/z of 35% and activation Q 0.25. The width of the precursor 
isolation window was 2 m/z and only multiply-charged precursor ions were selected 
for MS/MS. 
The MS and MS/MS scans were searched against NCBI database using the Mascot 
algorithm (Matrix Sciences). Variable modifications were deamidation (N and Q), 
oxidation (M), and carboxyamidomethylation (C). The precursor mass tolerance was 
10 ppm and the MS/MS mass tolerance was 0.8Da. Two missed cleavage was 
allowed and were accepted as a real hit protein with at least two high confidence 
peptides.  
 
IMMUNOPRECIPITATION OF ANKYRIN 
Isolated membranes (50μg) were mixed with rabbit anti-human ankyrin antibody in 
solution overnight at 4ºC. Protein G-coupled agarose beads (Invitrogen) were 
prepared according to the manufacturer’s protocol and then incubated with isolated 
membrane-antibody complexes for four hours at 4ºC. Agarose beads were then 
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washed twice to remove any non-specifically bound proteins prior to elution with 
0.1M glycine buffer (pH 3). 
 
FRAP ASSAY 
Measurement of the ferric reducing ability of plasma (FRAP) was undertaken using 
the assay based on the method of Benzie and Strain [35], slightly modified. The 
method is based on the principle of reduction of the ferric-tripyridyltriazine complex to 
the ferrous form, upon which an intense blue colour develops, and the change of 
absorbance is measured at 593nm (kinetic method). We have performed the 
measurement in a microplate format, by end-point approach. Briefly, 10μL of sample 
and 40μL of water were pipetted in microtiter plate in duplicate. After that, 200μL of 
working reagent were added in each well (а: acetate buffer pH 3.6; b: FeCl3 solution; 
c: 2,4,6,-tripyridyl-s-triazine solution; 10:1:1), and the reaction mixture was incubated 
for exactly 8 min at 37ºC [36]. The absorbance was measured on a Bio-Rad 
microplate reader model 680 XR, at 595nm, against reagent blank. Standards of 500, 
1,000 and 2,000μmol/L FeSO4 were used for calibration of the assay. 
 
CLINICAL CHEMISTRY ASSAYS 
The plasma concentrations of urea, creatinine, albumin, total cholesterol, 
triglycerides, HDL-cholesterol, and iron were measured on a standard clinical 
chemistry analyser (Dimension RxL Max, Siemens) in the routine clinical chemistry 
laboratory in Stip. 
 
STATISTICAL ANALYSIS 
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Numerical data were analysed by Microsoft Excel, and expressed as mean ± 
standard deviation. The normality of distribution was confirmed by the Kolmogorov-
Smirnov test, using Statistica 7 software. Statistical significance was assessed by the 
Student’s t-test: a) two-sample equal variance, or b) paired, as appropriate. 
Differences between groups or data sets were considered as statistically significant if 
the p value was lower than 0.05. 
The statistical significance of the coefficients of correlation was assessed according 
to the number of subjects within the group, using a statistical table [37]. 
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RESULTS 
 
CLINICAL DATA 
Patients who were included in this study (N=11) were on haemodialysis treatment for 
more than 18 months (mean duration of haemodialysis: 6 ± 3 years; range: from 2 to 
12 years), and were treated with a protocol of 3 haemodialysis sessions per week. 
Two of the patients had diabetes mellitus type 2 with diabetic retinopathy and 
concomitant cardiomyopathy. Cardiomyopathy was also present in another one 
patient. One of the patients was diagnosed with systemic lupus erythematosus, one 
with chronic gastritis, and six with arterial hypertension. A presentation of the co-
morbidities in the haemodialysed patients included in our study is given in Table 1. 
All of the patients were treated with a rHuEPO (Recormon). However, as measured 
before the haemodialysis session before the vitamin C supplementation, the blood 
haemoglobin concentrations were above 100g/L in only four patients, and none of 
them had a haemoglobin concentration above 115g/L. Six of the patients had low 
plasma iron concentrations. These data indicate a suboptimal erythropoietin/iron 
treatment. There was also a high and statistically significant correlation between the 
concentrations of plasma iron and blood haemoglobin (r = 0.77; p<0.01).  
Blood haemoglobin and haematocrit values did not change significantly as a result of 
the vitamin C supplementation (p>0.05 for both parameters; paired Student’s t-
test).The majority of patients showed an increase in iron concentration after the 
vitamin C treatment but the effect was not statistically significant (p>0.05; paired 
Student’s t-test). However, the strong correlation between haemoglobin and iron was 
reduced from 0.77 before vitamin C, to 0.02 after vitamin C supplementation, 
suggesting an interaction between the vitamin C and circulating iron. 
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In the chronically haemodialysed patients we observed a typical clinical chemistry 
profile consisting of high concentrations of plasma urea and creatinine, low plasma 
albumin, and low total and HDL-cholesterol (compared to the reference values). 
Following vitamin C supplementation none of these parameters changed significantly 
(p>0.05 for all parameters; paired Student’s t-test). 
The results from the routine haematology and clinical chemistry parameters are 
summarised in Table 2. 
 
FRAP ASSAY 
As a result of the vitamin C supplementation, there was a statistically significant 
increase in the concentration of total plasma antioxidants in chronically 
haemodialysed patients, from 1182 ± 241 to 1322 ± 306 μmol/L (p<0.05; paired 
Student’s t-test), as measured before the hemodialysis session by the FRAP assay. 
However, FRAP values were always higher in chronically haemodialysed patients 
compared to healthy controls (966 ± 113 μmol/L FeSO4), probably due to higher 
plasma concentration of small antioxidant molecules in chronic kidney disease. 
 
ELISA PROTEIN CARBONYLS 
As measured by the ELISA method, in the chronically haemodialysed patients not 
taking vitamin C the total erythrocyte membrane protein carbonyls were not 
significantly different before (1.03 ± 0.42 nmol carbonyl / mg protein) and after the 
single haemodialysis session (0.96 ± 0.73 nmol carbonyl / mg protein), p>0.05, 
paired Student’s t-test, and also in comparison with the healthy controls (0.96 ± 0.45 
nmol carbonyl / mg protein), p>0.05 for both comparisons. However, vitamin C 
supplementation decreased the content of the total erythrocyte membrane protein 
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carbonyls in the chronically haemodialysed patients before the single haemodialysis 
session (0.38 ± 0.19 nmol carbonyl / mg protein) which was statistically significant in 
comparison to a) the values measured before the single haemodialysis session 
without vitamin C supplementation (p<0.025, paired Student’s t-test) and b) the 
healthy controls (p<0.025). ELISA total protein carbonyl measurements in the 
isolated erythrocyte membranes are summarised in the Table 3, expressed as mean 
± standard deviation. 
There were no statistically significant correlations between total protein carbonyls in 
erythrocyte membranes and measures of anaemia (iron, haemoglobin and 
haematocrit) in patients on haemodialysis. Besides the complex aetiopathogenesis of 
anaemia in haemodialysis itself, these findings also suggest involvement of more 
subtle mechanisms of oxidative stress in induction of anaemia in haemodialysis, 
which we have further investigated. 
 
SDS-PAGE AND WESTERN BLOT ANALYSIS OF OXIDISED PROTEINS 
In contrast to the results obtained by the ELISA assay for total protein carbonyls, the 
western blot analysis demonstrated a well-defined heavily oxidised protein in the 
erythrocyte membranes isolated from the chronically haemodialysed patients, which 
was completely absent in the healthy controls. This oxidised protein was present in 
the erythrocyte membranes of chronically haemodialysed patients irrespective of 
treatment – haemodialysis session or vitamin C supplementation (arrow; Figure 2B). 
To investigate whether the difference in intensity of protein oxidation observed in 
chronically haemodialysed patients reflects differences in expression of the protein in 
the membranes of patients compared to controls, samples were run in parallel and 
stained with either Flamingo fluorescent protein stain (Bio-Rad) or underwent 
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western blot analysis for protein oxidation (Figure 2A and B respectively). The gels 
demonstrate the presence of the protein(s) of interest in both patients and healthy 
subjects, confirming the difference in western blot signal is due to protein oxidation 
rather than protein expression. In addition, this figure illustrates a difference in the 
distribution and predicted masses of erythrocyte membrane proteins in patients 
undergoing chronic haemodialysis with a slightly higher MW band present in controls 
but absent in patients. 
Subsequent analysis of integrated protein bands using ImageJ software has shown 
that intensity of carbonylation of the protein which is most sensitive to variable 
oxidation was reduced in average by 60% following haemodialysis (p<0.001; paired 
Student’s t-test), but ~20% after vitamin C supplementation (p>0.05; paired Student’s 
t-test). Samples from all three time points for each patient were analysed at the same 
time and were obtained for 7 patients along with 8 samples from the healthy control 
subjects. Data were normalised to healthy controls and show a decrease of 
carbonylation of the protein of interest as a result of the single haemodialysis session 
(Figure 3A). Decreased protein carbonyl content of this specific protein as a result of 
the vitamin C supplementation is depicted in Figure 3B. There was no significant 
difference in yield of protein recovered from erythrocyte membranes nor was there 
was no significant difference in % intensity for the band of interest relative to total 
protein stained (surrogate protein concentration) between patients, pre- and post-
treatment and controls (Table 4).   
 
MS ANALYSIS 
The major band which was heavily oxidised in patients but not in membrane proteins 
from control subjects indicated by an arrow in Figure 2 was digested with trypsin, 
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extracted from the gel and analysed by LC-MS/MS. The most significant identification 
was attributed to ankyrin, with 65% sequence coverage including both N- and C-
terminal residues and with an expected MW of 206kDa. There are many splice 
variants of ankyrin and it frequently undergoes modifications which can influence its 
electrophoretic mobility [38]. 
 
IMMUNOLOGICAL VALIDATION OF ANKYRIN IDENTITY 
To confirm ankyrin’s electrophoretic mobility in the SDS-PAGE gel conditions 
adopted here and its specific oxidation we also performed western blotting for ankyrin 
using an antibody raised against the regulatory domain, analysis of specific protein 
oxidation by western blot and immunoprecipitation. Figure 4 confirms that ankyrin 
migrates to the equivalent of a 75kDa standard on the gel, is a major oxidised band 
and the extent of oxidation alters with dialysis. 
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DISCUSSION 
We have shown that in ESRD patients, total erythrocyte membrane protein carbonyl 
concentrations are not different from healthy controls nor are affected by dialysis. 
However, total protein carbonyls are reduced by vitamin C supplementation. Detailed 
analysis of the major band which was susceptible to oxidation in ESRD erythrocytes 
by mass spectrometry, immune-precipitation and western blot confirmed its identity 
as ankyrin. Our SDS-PAGE gels of erythrocyte membrane proteins confirm findings 
of others that protein expression differs in ESRD patients [29]; 2D gel studies showed 
that tropomodulin 1 (47kDa) was elevated in pre-dialysis compared to controls and 
post-dialysis treatment whereas the 97kDa protein beta-adducin was elevated in 
patients irrespective of treatment. Changes in band intensity were not evident here 
by 1D SDS-PAGE at these previously reported molecular masses. Following 
oxidative damage, proteins are susceptible to both aggregation and fragmentation. 
Aggregated proteins are frequently excluded from SDS-PAGE gels, and we did 
observe lower band intensity at >100kDa and higher intensity of bands in membranes 
from ESRD consistent with the hypothesis of increased protein oxidation in ESRD. 
Both aggregation and fragmentation of proteins may affect erythrocyte membrane 
deformability.     
Although ESRD patients who are dependent on chronic haemodialysis treatment are 
widely recognised as having an oxidative stress related condition, the lack of 
significant difference in overall protein oxidation results are consistent with others 
[39]. The decrease in total protein oxidation after vitamin C intervention is again in 
accordance with our previous study; combined vitamin C / vitamin E antioxidant 
supplementation resulted in significant decrease of the plasma hydroperoxides of 
nearly 70% in chronically haemodialysed patients [40]. Together these data suggest 
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either the existence of some compensatory mechanism(s) to cope with the increased 
oxidative stress in these patients or that oxidation leads to enhanced fragility and 
lysis with greater chance for clearance of oxidised erythrocytes after haemodialysis. 
Ankyrin normally enables erythrocytes to resist shear forces experienced in the 
circulation through anchoring to cytoskeletal components such as spectrin. Moreover, 
individuals with reduced or defective ankyrin have a form of haemolytic anaemia [41]. 
While the effect of ankyrin oxidation on its capacity to resist shear forces is unknown, 
loss of function is a common observation in carbonylated, oxidised proteins. Ankyrin 
oxidised cells may be more fragile and more susceptible to haemolysis. One 
interpretation of the present data is that the more oxidised ankyrin bearing red cells 
are at increased probability of clearance after dialysis, so that overall the proportion 
of red cells with oxidised ankyrin and the extent of ankyrin oxidation is lower relative 
to total proteins in post-dialysis samples. In support of this, healthy control 
erythrocytes do not exhibit any significant oxidation of ankyrin. 
Anaemia in ESRD usually develops as a consequence of erythropoietin deficiency, 
and results in impaired quality of life and increased morbidity and mortality [42]. As a 
result, erythropoiesis stimulating agents are widely used for both increasing and 
maintaining of the haemoglobin levels in chronically haemodialysed patients [43,44]. 
However, there is evidence for an increased incidence of adverse effects in patients 
with haemoglobin concentrations of more than 130g/L [45], which needs further 
careful evaluation [46]. The present findings suggest that oxidised ankyrin may be 
used as both a stratifying medicines biomarker that identifies those patients most 
likely to require rHuEPO following haemolysis and a surrogate marker of disease for 
evaluating clinical benefit of intervention. 
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Increased oxidative damage in patients on chronic haemodialysis treatment has been 
considered to contribute to their increased cardiovascular risk [47-49], which cannot 
be completely explained by traditional cardiovascular risk factors and may be 
ameliorated with antioxidant intervention. Despite evidence for harmful effects in the 
general population of high doses of some common supplements (β-carotene, vitamin 
E, vitamin A) [50,51], there is evidence, although limited, that chronically 
haemodialysed patients could benefit from the use of antioxidants to prevent 
cardiovascular complications [52,53]. However, there are also some contradictory 
findings which suggest that the mechanism and consequences of oxidative damage 
in ESRD need closer examination before antioxidant interventions are evaluated [54]. 
Previous studies have largely focused on studying plasma biomarkers of oxidation, 
however, cell function is likely to be particularly important in disease pathogenesis. 
Here, we have described a methodology that has enabled us to evaluate specific 
membrane protein oxidation which can be extended to the study of monocyte 
membrane protein oxidation, since monocyte subset distribution and function are 
pivotal in balancing the risk of vascular disease [55]. In particular, a closer 
examination of oxidation in monocyte cell membranes of ESRD for proteins which 
are uniquely sensitive to oxidation or which may favour cell fragility may provide a 
useful insight into mechanisms and targets for intervention to mitigate risks of 
vascular complications. 
 
CONCLUSION 
Total erythrocyte membrane protein carbonyls from ESRD patients were reduced by 
vitamin C supplementation but not by dialysis. Using a western blot to detect oxidised 
proteins, one protein band, later identified as containing ankyrin, was found to be 
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oxidised in patients but not controls. Erythrocyte ankyrin oxidation was reduced 
significantly by 60% in all patients after dialysis and by 20% after 4 weeks vitamin C 
treatment when measured pre-dialysis. Strategies for preventing ankyrin oxidation 
may reduce erythocyte clearance, increase survival time and reduce anaemia. These 
findings are consistent with the observations that vitamin C is effective in increasing 
the haemoglobin concentrations in patients who are hypo-responsive on treatment 
with erythropoietin, and/or decreasing of the rHuEPO requirements [25,26].  
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Table 1. Co-morbidities in chronically haemodialysed patients 
 
Patient 
Diabetes 
mellitus 
type 2 
Retinopathy Cardiomyopathy Hypertension Lupus erythematosus Gastritis 
1   *    
2    *  * 
3 (A) * * * *   
4 (B)       
5 (F)    * *  
6    *   
7 (G)       
8 * * * *   
9 (C)       
10 (D)    *   
11 (E)       
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Table 2. Basic haematology and clinical chemistry profile in chronically 
haemodialysed patients 
 
 Before HD, before 
vitamin C 
supplementation 
Before HD, after 
vitamin C 
supplementation 
 
  Mean ± 
SD Range 
 Mean ± 
SD Range 
Reference 
range 
Haemoglobin 
(g/L) 92 ± 16 66 - 114 90 ± 14 66 - 110 110 – 165 
Haematocrit 
(%) 27.6 ± 4.4 20.0 – 33.0 27.9 ± 3.9 21.3 – 34.1 35.0 – 50.0 
Urea 
(mmol/L) 21.3 ± 6.4 12.4 – 33.2 20.5 ± 5.6 11.9 – 28.2 2.8 – 7.2 
Creatinine 
(μmol/L) 778 ± 225 557 - 1299 776 ± 198 547 - 1218 58 – 110 
Albumin 
(g/L) 34.8 ± 3.4 29.8 – 40.7 35.1 ± 3.4 30.1 – 41.4 35.0 – 52.0 
Total 
cholesterol 
(mmol/L) 
3.7 ± 0.9 1.9 – 4.9 3.6 ± 0.8 1.8 – 4.6 4.1 – 5.2 
Triglycerides 
(mmol/L) 1.9 ± 0.9 0.7 – 3.4 1.7 ± 0.8 0.7 – 3.2 0.3 – 1.7 
HDL-
cholesterol 
(mmol/L) 
0.75 ± 0.26 0.41 – 1.27 0.76 ± 0.28 0.40 – 1.30 1.00 – 2.00 
Iron  
(μmol/L) 11.5 ± 6.9 1.9 – 22.8 12.1 ± 6.8 4.8 – 24.4 10.7 – 32.2 
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* Statistically significant (p<0.025) in comparison to A and D 
 
  
Table 3. TOTAL PROTEIN CARBONYLS IN ISOLATED 
ERYTHROCYTE MEMBRANES  (nmol carbonyl / mg protein) 
    
A. Chronically 
haemodialysed 
patients, without 
vitamin C 
supplementation, 
before single 
haemodialysis 
session 
B. Chronically 
haemodialysed 
patients, without 
vitamin C 
supplementation, 
after single 
haemodialysis 
session 
C. Chronically 
haemodialysed 
patients, with 
vitamin C 
supplementation, 
before single 
haemodialysis 
session 
D. Healthy 
controls 
 
1.03 ± 0.42 0.96 ± 0.73 0.38* ± 0.19 0.96 ± 0.45 
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Table 4. Membrane protein concentration and % of total protein as ankyrin by 
densitometry following Flamingo staining of SDS-PAGE 
 
 Protein extracted 
from erythrocyte 
membrane 
(mg/ml) 
Protein on 
parallel gels 
visualised by 
Coomassie (AU) 
% ankyrin 
intensity of total 
protein 
Patients, before 
HD session, 
without vit. C 
supplementation 
1.68±0.22 1103 + 205 3.07±0.90 
Patients, after 
HD session, 
without vit. C 
supplementation 
2.14±0.69 968 + 172 2.74±0.70 
Patients, before 
HD session, 
with vit. C 
supplementation 
1.85±0.23 1017 + 138 3.22±0.65 
Healthy subjects 2.29±0.19 960 + 176 2.40±0.47 
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26 chronically 
haemodialysed patients 
from the two morning 
shifts
11 patients (on haemodialysis for 
more than 1 year) who do not 
take any vitamins or 
supplements are consented and 
enrolled in the study
13 patients take i.v. vitamin C 
500mg after each haemodialysis 
session
1 patient take oral 
vitamin C 1000mg 
per day
1 patient is on 
haemodialysis for 
less than 1 year
DAY 1 - SAMPLING
Point 1 Point 2
DAY 2 – Start of the 
vitamin C 
supplementation
DAY 28 – Last day 
of the vitamin C 
supplementation
DAY 29 –
SAMPLING
Point 3
Vitamin C supplementation 
2 x 500mg per day
Regular standard treatment 
with 3 haemodialysis 
sessions per week*
 
 
Figure 1. Study design – schematic presentation. Point 1: Day 1, immediately 
before the start of the haemodialysis session, fasting blood samples. Point 2: Day 1, 
at the end of the haemodialysis session. Point 3: Day 29, immediately before the 
start of the haemodialysis session, fasting blood samples. 
*During the study period all parameters of the haemodialysis sessions were kept 
constant. None of the patients had any infectious or inflammatory condition. 
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A)                                        1       2      3      4      5       6       
 
 
 
B)                                          1      2     3       4     5       6       
 
Figure 2. Erythrocyte membrane protein distribution and oxidation are altered 
in patients who are chronically haemodialysed. A) Erythrocyte membrane 
proteins stained with Flamingo fluorescent protein stain. B) Western blot analysis of 
oxidised erythrocyte membrane proteins. 
BSA=oxidised bovine serum albumin standard. 
Lane 1: Subject 9 (chronically haemodialysed patient) without vitamin C 
supplementation, before haemodialysis session. Lane 2: Subject 9 without vitamin C, 
after haemodialysis session. Lane 3: Subject 9 with vitamin C, before haemodialysis 
session. Lanes 4 and 5 are from 2 healthy subjects and lane 6 is the positive control 
(oxidised BSA). 
The arrow highlights the protein most sensitive to variable oxidation which was 
extracted for identification by MS. 
 
  
BSA 
BSA 
Page 38 of 39 
 
 
A) 
 
 
 
B) 
 
 
 
Figure 3. Erythrocyte membrane protein which is most sensitive to variable 
oxidation is reduced after the single haemodialysis session (A) and vitamin C 
supplementation (B). Patient protein oxidation was normalised to control membrane 
protein oxidation. 
 
  
0
2
4
6
8
10
12
14
16
18
20
1. Before haemodialysis
session, without vitamin C
2. After haemodialysis session,
without vitamin C
Pr
ot
ei
n 
ox
id
at
io
n 
- n
or
m
al
is
ed
 v
al
ue
s 
Patient A
Patient B
Patient C
Patient D
Patient E
Patient F
Patient G
0
2
4
6
8
10
12
14
16
18
20
1. Before haemodialysis
session, without vitamin C
3. Before haemodialysis
session, with vitamin C
Pr
ot
ei
n 
ox
id
at
io
n 
- n
or
m
al
is
ed
 v
al
ue
s 
Patient A
Patient B
Patient C
Patient D
Patient E
Patient F
Patient G
Page 39 of 39 
 
KDa
250 
150 
100 
75 
 
         M  RBC     M  RBC      M   W1  W2  E1  E2 
A  B  C  
 
Figure 4. Ankyrin is oxidised in erythrocytes (red blood cells; RBC) from a 
patient undergoing chronic haemodialysis. A) Western blotting for protein 
carbonyls of erythrocyte membrane proteins. B) Coomassie stained gel of 
erythrocyte membrane proteins. C) Coomassie stained gel of ankyrin 
immunoprecipitation from erythrocyte membranes, where W=wash and E=elution 
and M=markers. 
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